Relapsed or Refractory Haematopoietic Malignancies, (NCT04767308)
Sponsors:
Huazhong University of Science and Technology
Sponsors:
Huazhong University of Science and Technology
IND Enabling
Phase I
Phase II
Phase III
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Shanghai IASO Biotechnology
Main focus: Gene editing for the treatment of cancer
Company stage: Clinical
Diseases: T- and B-cell malignancies
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai and Nanjing, China
Website: http://www.iasobio.com/
Pipeline: http://www.iasobio.com/proline.php
Shanghai IASO Biotechnology develops next generation allogeneic CAR-T cell therapies and uses CRISPR to make the CAR-T cells fratricide-resistent. The company is currently developing multiple pre-clinical programmes using CRISPR, to treat T- and B-cell malignancies.
Tags
Shanghai IASO Biotechnology Co., Ltd
